scholarly journals Effects of dietary nitrate supplementation on symptoms of acute mountain sickness and basic physiological responses in a group of male adolescents during ascent to Mount Everest Base Camp

Nitric Oxide ◽  
2016 ◽  
Vol 60 ◽  
pp. 24-31 ◽  
Author(s):  
Philip J. Hennis ◽  
Kay Mitchell ◽  
Edward Gilbert-Kawai ◽  
Vassiliki Bountziouka ◽  
Angie Wade ◽  
...  
2017 ◽  
Vol 123 (4) ◽  
pp. 983-992 ◽  
Author(s):  
Gabriella M. K. Rossetti ◽  
Jamie H. Macdonald ◽  
Lee J. Wylie ◽  
Samuel J. Little ◽  
Victoria Newton ◽  
...  

Dietary nitrate supplementation enhances sea level performance and may ameliorate hypoxemia at high altitude. However, nitrate may exacerbate acute mountain sickness (AMS), specifically headache. This study investigated the effect of nitrate supplementation on AMS symptoms and exercise responses with 6-h hypoxia. Twenty recreationally active men [age, 22 ± 4 yr, maximal oxygen consumption (V̇o2max), 51 ± 6 ml·min−1·kg−1, means ± SD] completed this randomized double-blinded placebo-controlled crossover study. Twelve participants were classified as AMS− on the basis of Environmental Symptoms Questionnaire [Acute Cerebral Mountain Sickness score (AMS-C)] <0.7 in both trials, and five participants were classified as AMS+ on the basis of AMS-C ≥0.7 on placebo. Five days of nitrate supplementation (70-ml beetroot juice containing ~6.4 mmol nitrate daily) increased plasma NO metabolites by 182 µM compared with placebo but did not reduce AMS or improve exercise performance. After 4-h hypoxia [inspired O2 fraction ([Formula: see text]) = 0.124], nitrate increased AMS-C and headache severity (visual analog scale; whole sample ∆10 [1, 20] mm, mean difference [95% confidence interval]; P = 0.03) compared with placebo. In addition, after 5-h hypoxia, nitrate increased sense of effort during submaximal exercise (∆7 [−1, 14]; P = 0.07). In AMS−, nitrate did not alter headache or sense of effort. In contrast, in AMS+, nitrate increased headache severity (∆26 [−3, 56] mm; P = 0.07), sense of effort (∆14 [1, 28]; P = 0.04), oxygen consumption, ventilation, and mean arterial pressure during submaximal exercise. On the next day, in a separate acute hypoxic exercise test ([Formula: see text] = 0.141), nitrate did not improve time to exhaustion at 80% hypoxic V̇o2max. In conclusion, dietary nitrate increases AMS and sense of effort during exercise, particularly in those who experience AMS. Dietary nitrate is therefore not recommended as an AMS prophylactic or ergogenic aid in nonacclimatized individuals at altitude. NEW & NOTEWORTHY This is the first study to identify that the popular dietary nitrate supplement (beetroot) does not reduce acute mountain sickness (AMS) or improve exercise performance during 6-h hypoxia. The consumption of nitrate in those susceptible to AMS exacerbates AMS symptoms (headache) and sense of effort and raises oxygen cost, ventilation, and blood pressure during walking exercise in 6-h hypoxia. These data question the suitability of nitrate supplementation during altitude travel in nonacclimatized people.


2019 ◽  
Vol 20 (2) ◽  
pp. 192-197 ◽  
Author(s):  
Martin Burtscher ◽  
Michael Philadelphy ◽  
Hannes Gatterer ◽  
Johannes Burtscher ◽  
Martin Faulhaber ◽  
...  

1986 ◽  
Vol 80 (1) ◽  
pp. 32-36 ◽  
Author(s):  
Richard N.W. Wohns ◽  
Michael Colpitts ◽  
Thomas Clement ◽  
Anton Karuza ◽  
W.Ben Blackett ◽  
...  

2015 ◽  
Vol 27 (3) ◽  
pp. 82-86
Author(s):  
Z Mahomed ◽  
D Martin ◽  
E Gilbert ◽  
CC Grant ◽  
J Patricios ◽  
...  

Background. Acute mountain sickness (AMS) is an ever-increasing burden on the health sector. With reported incidences of greater than 50%, coupled with the fact that recreational activities at high altitude are gaining increasing popularity, more persons are developing AMS. Physicians are therefore increasingly faced with the task of managing and preventing AMS.Objectives. The pathophysiology of AMS is poorly understood, with little understanding of risk factors for the development of AMS. This research aimed to identify epidemiological and physiological risk factors for development of AMS.Methods. This study is a questionnaire-based study conducted in London and at Everest Base Camp, in which 116 lowlanders were invited to participate and fill in a questionnaire to identify potential risk factors in their history that may have contributed to development of or protection against AMS.Results. A total of 89 lowlanders enrolled in the study. Thirty-seven of the participants had AMS at  Everest Base Camp, giving a prevalence of 42%. Of the demographic variables, only weight and body  mass index (BMI) were statistically significantly associated with AMS, with those who weighed less or had a lower BMI more likely to get AMS. Previous high-altitude experience was also associated with AMS, with those who had such experience less likely to get AMS.Conclusion. Predicting AMS and furthering our understanding of the pathophysiology of AMS will be of tremendous benefit. Further research is needed in this regard.


1995 ◽  
Vol 79 (2) ◽  
pp. 487-492 ◽  
Author(s):  
S. S. Purkayastha ◽  
U. S. Ray ◽  
B. S. Arora ◽  
P. C. Chhabra ◽  
L. Thakur ◽  
...  

The study assessed physiological responses to induction to high altitude first to 3,500 m and then to 4,200 m and compared the time course of altitude acclimatization in two groups of male volunteers. The acutely inducted group was transported by aircraft (AI) to 3,500 m in 1 h, whereas the gradually inducted group was transported by road (RI) in 4 days. Baseline recordings of basal cardiovascular, respiratory, and blood gas variables were monitored at sea level as well as at 3,500 m on days 1, 3, 5, and 7. Blood gases were measured on day 10 also. After 15 days at 3,500 m, the subjects were inducted to 4,200 m by road, and measurements were repeated on days 1, 3, and 5, except blood gas variables, which were done on day 10 only. Acute mountain sickness symptoms were recorded throughout. The responses of RI were stable by day 3 of induction at 3,500 m, whereas it took 5 days for AI. Four days in transit for RI appear equivalent to 2 days at 3,500 m for AI. Acclimatization schedules of 3 and 5 days, respectively, for RI and AI are essential to avoid malacclimatization and/or high-altitude illness. Both groups took 3 days at 4,200 m to attain stability for achieving acclimatization.


Neurosurgery ◽  
1985 ◽  
Vol 16 (5) ◽  
pp. 693-695
Author(s):  
Richard N. W. Wohns ◽  
Michael Colpitts ◽  
Tom Clement ◽  
Anton Karuza

Abstract The authors report a case of acute mountain sickness (AMS) experienced by a support member of the Ultima Thule Everest Expedition. The subject arrived at the 17,000-ft base camp by truck and then developed the symptoms of AMS over the following 72 hours. Flash-induced visual evoked responses (VERs), tetrapolar impedance pulmonary plethysmography, and oxygen saturation measurements were performed. These changed from normal before the onset of his symptoms to abnormal during the height of the symptoms and reverted to normal after treatment. This is the first reported case of AMS monitored with VERs. It has been postulated that AMS may be an early form of cerebral edema, and this report corroborates this hypothesis.


2012 ◽  
Vol 113 (5) ◽  
pp. 736-745 ◽  
Author(s):  
Evi Masschelein ◽  
Ruud Van Thienen ◽  
Xu Wang ◽  
Ann Van Schepdael ◽  
Martine Thomis ◽  
...  

Exercise tolerance is impaired in hypoxia, and it has recently been shown that dietary nitrate supplementation can reduce the oxygen (O2) cost of muscle contractions. Therefore, we investigated the effect of dietary nitrate supplementation on arterial, muscle, and cerebral oxygenation status, symptoms of acute mountain sickness (AMS), and exercise tolerance at simulated 5,000 m altitude. Fifteen young, healthy volunteers participated in three experimental sessions according to a crossover study design. From 6 days prior to each session, subjects received either beetroot (BR) juice delivering 0.07 mmol nitrate/kg body wt/day or a control drink (CON). One session was in normoxia with CON (NORCON); the two other sessions were in hypoxia (11% O2), with either CON (HYPCON) or BR (HYPBR). Subjects first cycled for 20 min at 45% of peak O2 consumption (VO2peak; EX45%) and thereafter, performed a maximal incremental exercise test (EXmax). Whole-body VO2, arterial O2 saturation (%SpO2) via pulsoximetry, and tissue oxygenation index of both muscle (TOIM) and cerebral (TOIC) tissue by near-infrared spectroscopy were measured. Hypoxia per se substantially reduced VO2peak, %SpO2, TOIM, and TOIC (NORCON vs. HYPCON, P < 0.05). Compared with HYPCON, VO2 at rest and during EX45% was lower in HYPBR ( P < 0.05), whereas %SpO2 was higher ( P < 0.05). TOIM was ∼4-5% higher in HYPBR than in HYPCON both at rest and during EX45% and EXmax ( P < 0.05). TOIC as well as the incidence of AMS symptoms were similar between HYPCON and HYPBR at any time. Hypoxia reduced time to exhaustion in EXmax by 36% ( P < 0.05), but this ergolytic effect was partly negated by BR (+5%, P < 0.05). Short-term dietary nitrate supplementation improves arterial and muscle oxygenation status but not cerebral oxygenation status during exercise in severe hypoxia. This is associated with improved exercise tolerance against the background of a similar incidence of AMS.


2021 ◽  
Vol 9 (7) ◽  
Author(s):  
Alexandra B. Cobb ◽  
Denny Z. H. Levett ◽  
Kay Mitchell ◽  
Wynne Aveling ◽  
Daniel Hurlbut ◽  
...  

BMJ ◽  
2004 ◽  
Vol 328 (7443) ◽  
pp. 797 ◽  
Author(s):  
Jeffrey H Gertsch ◽  
Buddha Basnyat ◽  
E William Johnson ◽  
Janet Onopa ◽  
Peter S Holck

AbstractObjective To evaluate the efficacy of ginkgo biloba, acetazolamide, and their combination as prophylaxis against acute mountain sickness.Design Prospective, double blind, randomised, placebo controlled trial.Setting Approach to Mount Everest base camp in the Nepal Himalayas at 4280 m or 4358 m and study end point at 4928 m during October and November 2002.Participants 614 healthy western trekkers (487 completed the trial) assigned to receive ginkgo, acetazolamide, combined acetazolamide and ginkgo, or placebo, initially taking at least three or four doses before continued ascent.Main outcome measures Incidence measured by Lake Louise acute mountain sickness score ≥ 3 with headache and one other symptom. Secondary outcome measures included blood oxygen content, severity of syndrome (Lake Louise scores ≥ 5), incidence of headache, and severity of headache.Results Ginkgo was not significantly different from placebo for any outcome; however participants in the acetazolamide group showed significant levels of protection. The incidence of acute mountain sickness was 34% for placebo, 12% for acetazolamide (odds ratio 3.76, 95% confidence interval 1.91 to 7.39, number needed to treat 4), 35% for ginkgo (0.95, 0.56 to 1.62), and 14% for combined ginkgo and acetazolamide (3.04, 1.62 to 5.69). The proportion of patients with increased severity of acute mountain sickness was 18% for placebo, 3% for acetazoalmide (6.46, 2.15 to 19.40, number needed to treat 7), 18% for ginkgo (1, 0.52 to 1.90), and 7% for combined ginkgo and acetazolamide (2.95, 1.30 to 6.70).Conclusions When compared with placebo, ginkgo is not effective at preventing acute mountain sickness. Acetazolamide 250 mg twice daily afforded robust protection against symptoms of acute mountain sickness.


Sign in / Sign up

Export Citation Format

Share Document